Five Long Years: Building A Business For An Uncertain Tomorrow
You may also be interested in...
On its face, comparative effectiveness research and its new cousin, patient-centered outcomes research, would seem to support, if not enable, personalized medicine. But as currently established in the US, there is little conceptual overlap. That’s largely because much CER and patient-centered outcomes research steer clear of anything that smacks of the development of cost data, which personalized medicine may need to truly make its value proposition.
Personalized medicine remains a worthy goal, but for payers the evidence just isn't there yet to support reimbursement of much diagnostic testing, the Tufts Center for the Study of Drug Development concludes in its July/August Impact Report.
Moderna's vaccine has shown encouraging early results in younger adults, but over-55s and over-70s cohorts represent a bigger safety and efficacy hurdle.